{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-083559","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2026-07-14T21:06:03+00:00","discovered_at":"2026-07-14T21:08:00.279561+00:00","generated_at":"2026-07-14T21:08:04.286176+00:00","sec_items":["1.01","2.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Capricor signs lease for 171K sq ft HQ; rent abatement, FDA approval contingency","bullets":["Lease for 171,000 rentable sq ft at 9625 Towne Centre Dr, San Diego, as new HQ with manufacturing cleanrooms.","Initial monthly base rent ~$958K ($5.60/sq ft), escalating 3% annually; 18-month full rent abatement then 6-month partial.","Lease term 138 months from rent commencement; commencement tied to earlier of FDA approval satisfaction or Dec 31, 2026.","If FDA approval of Deramiocel for Duchenne muscular dystrophy not obtained by Dec 31, 2026, either party may terminate.","Security deposit ~$958K in cash or letter of credit; Capricor responsible for taxes, insurance, operating costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-083559","json":"https://secwatch.observer/filing/0001104659-26-083559.json","markdown":"https://secwatch.observer/filing/0001104659-26-083559.md","text":"https://secwatch.observer/filing/0001104659-26-083559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926083559/0001104659-26-083559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926083559/capr-20260709x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T21:08:04.286176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}